On the morning of December 22, Laikai Pharmaceutical announced on the Hong Kong Stock Exchange that the group has initiated the enrollment of participants in the LAE102 Phase I multi-dose expansion study for the treatment of obesity in China, and has completed the administration of the first test subject.

On the morning of December 22, Laikai Pharmaceutical announced on the Hong Kong Stock Exchange that the group has initiated the enrollment of participants in the LAE102 Phase I multi-dose expansion study for the treatment of obesity in China, and has completed the administration of the first test subject.